Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 63Active not recruiting 24Terminated 6Recruiting 5Unknown 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Glioma 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

trastuzumab deruxtecan 2TIC10 compound 2infigratinib 1belumosudil 1KD025 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Has announcements × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT03248492 2025-06-26

DESTINY-Breast01

Daiichi Sankyo

Phase 2 Terminated
253 enrolled 21 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Daiichi Sankyo

Phase 2 Terminated
181 enrolled 17 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated
159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

NCT02150967 2023-07-03

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

QED Therapeutics, a BridgeBio company

Phase 2 Terminated
143 enrolled 25 charts 1 FDA
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡